Menu Search
Equities

Merit Medical Systems Inc

MMSI:NSQ

Merit Medical Systems Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)100.21
  • Today's Change1.50 / 1.52%
  • Shares traded555.85k
  • 1 Year change+44.85%
  • Beta0.8713
Data delayed at least 15 minutes, as of Sep 19 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 18-Sep-24
Select bar for recommendation details.
Recommendations18-Sep-24
Buy4
Outperform5
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The 11 analysts offering 12 month price targets for Merit Medical Systems Inc have a median target of 105.00, with a high estimate of 125.00 and a low estimate of 94.00. The median estimate represents a 4.76% increase from the last price of 100.23.
High24.7%125.00
Med4.8%105.00
Low-6.2%94.00

Earnings history & estimates in USD

On Aug 01, 2024, Merit Medical Systems Inc reported 2nd quarter 2024 earnings of 0.92 per share. This result exceeded the 0.87 consensus of the 10 analysts covering the company and exceeded last year's 2nd quarter results by 13.58%.
The next earnings announcement is expected on Oct 24, 2024.
Average growth rate+3.78%
Merit Medical Systems Inc reported annual 2023 earnings of 3.01 per share on Feb 28, 2024.
Average growth rate+20.51%
More ▼

Revenue history & estimates in USD

Merit Medical Systems, Inc. had 2nd quarter 2024 revenues of 338.00m. This bettered the 334.55m consensus of the 11 analysts covering the company. This was 13.59% above the prior year's 2nd quarter results.
Average growth rate+1.40%
Merit Medical Systems, Inc. had revenues for the full year 2023 of 1.26bn. This was 9.24% above the prior year's results.
Average growth rate+6.18%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.